
Disease & Drugs
Research
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Research
ResearchClosed-Loop Insulin Delivery Systems: The New StandardClosed-loop insulin delivery systems are advancing Type 1 diabetes care through automated insulin dosing, improved time-in-range, and reduced hypoglycemia. Written…Fact-Checked
LifestyleSmall Steps, Longer Lives: Lancet Study Links Minutes of Movement to Lower Death RiskPhoto by Arek Adeoye on Unsplash A new Lancet meta-analysis shows that adding just a few minutes of daily physical…Fact-Checked
ResearchINGREZZA Shows Nearly Double VMAT2 Target Occupancy Compared to AUSTEDO XR in First Head-to-Head Study, Neurocrine ReportsNeurocrine Biosciences reports first head-to-head PET imaging data showing INGREZZA achieved nearly double VMAT2 target occupancy compared with AUSTEDO XR…Fact-Checked
ResearchAbbott Launches Libre Assist in Libre App to Improve In-the-Moment Food Decisions for People with DiabetesAbott…Fact-Checked
ResearchPolyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral BlockerPolyrizon Ltd. has submitted a Pre-Request for Designation (Pre-RFD) to the U.S. Food and Drug Administration for PL-16, its investigational Viral Blocker nasal spray.Fact-Checked
Drugs Safety AlertNimesulide’s Rise and Reckoning in India: Ending with a Nationwide Ban on High-Dose UseA detailed look at nimesulide in India, from its widespread use to mounting safety concerns, regulatory scrutiny, and the final…Fact-Checked
ResearchFDA Issues Third CRL for Outlook Therapeutics’ ONS-5010/LYTENAVA in Wet AMD – What It MeansFDA issued a Complete Response Letter for Outlook Therapeutics’ ONS-5010/LYTENAVA for wet AMD, requesting more confirmatory data. Learn what this…Fact-Checked
ResearchSemaglutide and Eye Health: A Look at NAION RiskSemaglutide has been linked to rare cases of non-arteritic anterior ischemic optic neuropathy (NAION). Learn what current studies, regulators, and…Fact-Checked
ResearchCorcept Therapeutics Receives FDA Complete Response Letter for Relacorilant in Hypertension Secondary to HypercortisolismCorcept Therapeutics has received an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Learn what the CRL…Fact-Checked
ResearchGenmab Halts Clinical Development of Acasunlimab After Portfolio Review, Shifts Focus to Late-Stage Oncology PipelineGenmab A/S has announced that it will discontinue clinical development of its investigational cancer therapy acasunlimab after a strategic portfolio review.Fact-Checked
Drugs Safety AlertFDA Says PFAS Safety in Cosmetics Remains Uncertain Due to Data GapsFDA’s MoCRA report finds insufficient data to determine the safety of PFAS, often called forever chemicals, in cosmetics, highlighting major…Fact-Checked
New Drug ApprovalGrifols’ FESILTY (Fibrinogen): Evidence, Safety, and Clinical Use ExplainedThe U.S. FDA has approved FESILTY (fibrinogen, human-chmt) for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia.…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.